Reditux, a biosimilar rituximab - the world’s first monoclonal antibody biosimilar was launched by Dr. Reddy’s in 2007. It is used to treat Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukaemia and Rheumatoid Arthritis. This monoclonal antibody has helped over half a million patients worldwide.
2-8 degrees Celsius (refrigerate), Do not freeze.
Vial containing concentrate for solution for infusion.
Intravenous (IV) (upon prescription only and administered by a healthcare provider.)
Rituximab is a chimeric murine/human monoclonal immunoglobulin G1 antibody that targets CD20, which is a B-cell differentiation marker. CD20 is a cell surface marker specifically found on late pre-B and mature B lymphocytes and is not found on other cell types or free in circulation. The only binding site for Rituximab is CD20 on B-cells. The binding of Rituximab to cell surface CD20 located on the B lymphocytes results in the destruction of the lymphocyte by three potential mechanisms: complement-dependent cytotoxicity, stimulation of apoptosis, and antibody-dependent cytotoxicity.